Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations
Table 2
Current FDA-approved intravenous iron preparations [8, 10, 27–36].
Trade name
Dexferrum (iron dextran injection, USP)
INFeD (iron dextran injection, USP)
Ferrlecit (sodium ferric gluconate complex in sucrose injection)
Venofer (iron sucrose injection, USP)
Feraheme (ferumoxytol)
Injectafer (ferric carboxymaltose injection)
Manufacturer
American Regent, Inc.
Actavis Pharma, Inc.
Sanofi-Aventis
American Regent, Inc.
AMAG Pharmaceuticals
American Regent, Inc.
Test dose
Yes
Yes
No
No
No
No
Black box warning
Yes
Yes
No
No
Yes
No
FDA-approved indications
Iron deficiency where oral iron administration is unsatisfactory or impossible
Iron deficiency where oral iron administration is unsatisfactory or impossible
Iron deficiency anemia in adult and pediatric CKD patients receiving hemodialysis and receiving ESAs
IDA in adult and pediatric patients with non-dialysis-dependent, hemodialysis dependent, and peritoneal dialysis-dependent CKD
IDA in adult patients with CKD
IDA in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or adult patients with non-dialysis-dependent CKD
Total cumulative dose
Dependent on patient’s total iron requirement
Dependent on patient’s total iron requirement
1000 mg
1000 mg
1020 mg
1500 mg
CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; IDA = iron deficiency anemia. American Regent, Inc., is the human drug division of Luitpold Pharmaceuticals, Inc., Shirley, NY.
